JP Patent

JP6038128B2 — レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー

Assigned to Eisai R&D Management Co Ltd · Expires 2016-12-07 · 9y expired

What this patent protects

Patent listed against lenvatinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
JP6038128B2
Jurisdiction
JP
Classification
—
Expires
2016-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.